Eli Lilly bets on an RNA base editing outfit leveraging the body's own enzymes to reverse mutations
With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player focused around neuroscience could now add even more bite to Lilly’s bark.
Lilly will pay $50 million in upfront cash and equity and up to $1.25 billion in downstream milestones for access to five RNA editing candidates from Dutch biotech ProQR Therapeutics, which is using edited oligonucleotides to kick off an RNA base editing system initiated by the body’s own enzymes, the partners said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
